MedPath

Variation of Physical Activity, Measured by the Number of Steps Per Day, After Artificial Urinary Sphincter Implantation

Not Applicable
Recruiting
Conditions
Urinary Incontinence
Interventions
Other: Activity sensor
Registration Number
NCT04008108
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Brief Summary

The management of urinary incontinence seems to improve daily activities and the practice of physical activity, according to the literature. Unfortunately, all of these studies are based on self-questionnaires with the disadvantages of self-evaluation, more subjective.

For several years activity sensors have been used in the medical field (rheumatology, cardiology, diabetology, etc.). They allowed the evaluation of physical activity in real life situations, whether to evaluate the degree of severity of a pathology or the impact of a new treatment on the resumption of activities.

Activity sensors are devices that transform body motion into digital measurements. They provide detailed information on the frequency, duration, intensity and type of movement to determine, for example, the number of steps taken, the distance traveled, calories burned and the quality of sleep.

It is hypothesized that urinary incontinence treatment can increase physical activity and so improve the quality of life of patients, that can be measure by activity sensors.

Detailed Description

The management of urinary incontinence seems to improve daily activities and the practice of physical activity, according to the literature. Unfortunately, all of these studies are based on self-questionnaires with the disadvantages of self-evaluation, more subjective.

The artificial urinary sphincter (AUS) implantation is an effective treatment on stress urinary incontinence in men and women. Currently the PadTest/24 hours is the reference for his evaluation.

For several years activity sensors have been used in the medical field (rheumatology, cardiology, diabetology, etc.). They allowed the evaluation of physical activity in real life situations, whether to evaluate the degree of severity of a pathology or the impact of a new treatment on the resumption of activities.

Activity sensors are devices that transform body motion into digital measurements. They provide detailed information on the frequency, duration, intensity and type of movement to determine, for example, the number of steps taken, the distance traveled, calories burned and the quality of sleep.

It is hypothesized that urinary incontinence treatment can increase physical activity and so improve the quality of life of patients, that can be measure by activity sensors.

The research is a monocentric, prospective study.

The Primary objective of this study is to evaluate the variation of physical activity measured by the number of steps per day, before AUS implantation and 3 months after the activation of the sphincter.

For that, the primary outcome measure is the number of steps per day measured 24h/24 for 7 consecutive days by activity sensor, before AUS implantation and 3 months after activation of the sphincter.

All adult patients (men and women) with a surgical indication for urinary incontinence treatment by AUS in the urology department of Pitié-Salpêtrière hospital will be screened for eligibility.

Four visits will be programed as standard of care :

* During the first visit, patients will be informed of the study and their agreement will be recorded. Patients' eligibility will be checked.

* AUS implantation

* AUS activation

* AUS follow-up, around fourteen weeks after activation The activity sensor, the Pad/Test/24 hours and questionnaires such as eQOL will be performed at home before AUS implantation, 1 month after the AUS activation and 3 months after the AUS activation.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
45
Inclusion Criteria
  • Age ≥ 18 years
  • Surgical indication of urinary incontinence treatment with artificial urinary sphincter implantation
  • Patient informed and not opposed to the research
  • Reading and speaking comprehension of the French language
Exclusion Criteria
  • Patient under guardianship or curators
  • Contraindication to the placement of an artificial urinary sphincter
  • Patients requiring walking assistance (canes, walker, wheelchair)
  • Revisions of artificial urinary sphincter already implanted
  • Cognitive impairment deemed incompatible with research

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Patient with urinary incontinenceActivity sensorPatient with urinary incontinence
Primary Outcome Measures
NameTimeMethod
Number of steps per day, during 7 days at 3 months of the AUS activationThrough the study completion, an average of 8 months

Number of steps per day measured 24h/24 for 7 consecutive days by the activity sensor, at 3 months after activation of the AUS.

3 months after activation of the AUS is corresponding to 32 weeks from the inclusion (8 months).

Secondary Outcome Measures
NameTimeMethod
PAD-test / 24hThrough the study completion, an average of 8 months

PAD-test / 24h performed at home preoperatively and 3 months after activation of AUS.

3 months after activation of the AUS is corresponding to 32 weeks from the inclusion (8 months).

Other activity sensor data (heart rate)Through the study completion, an average of 8 months

Heart rate measured by the activity sensor preoperatively and at 1 month and 3 months after activation of the AUS.

3 months after activation of the AUS is corresponding to 32 weeks from the inclusion (8 months).

Other activity sensor data (sedentary and activity percentage in the day)Through the study completion, an average of 8 months

Sedentary and activity percentage a day measured by the activity sensor preoperatively and at 1 month and 3 months after activation of the AUS.

3 months after activation of the AUS is corresponding to 32 weeks from the inclusion (8 months).

International Physical Activity Questionnaire (IPAQ)Through the study completion, an average of 8 months

IPAQ is a 8 items questionnaire that assess 3 types of activity (walking, moderate-intensity activities and vigorous-intensity activities) in the following domains: leisure time, domestic/gardening, work-related, transport-related. It provide separate scores on each type of activity. Computation of the total score requires summation of the duration (in minutes) and frequency (days) of each type of activity. A Metabolic Equivalent Task (MET) is a multiple of the estimated resting energy expenditure.

Walking MET-minutes/week=3.3\*walking minutes\*walking days Moderate MET-minutes/week=4.0\*moderate-intensity activity minutes\*moderate days Vigorous MET-minutes/week=8.0\*vigorous-intensity activity minutes\*vigorous-intensity days Total =sum of Walking+Moderate+Vigorous METminutes/week scores.

Questionnaire IPAQ fulfilled before implantation and 3 months after activation of AUS.

3 months after activation of the AUS is corresponding to 32 weeks from the inclusion (8 months).

Number of steps per day, during 7 days, at 1 month of the AUS activationThrough the study completion, an average of 6 months

Number of steps per day measured 24h/24 for 7 consecutive days by the activity sensor, at 1 month after activation of the AUS.

1 month after activation of the AUS is corresponding to 24 weeks from the inclusion (6 months).

Incontinence Quality of Life (I-QOL)Through the study completion, an average of 8 months

I-QOL is a self-report Quality of Life measure specific to urinary problems. The I-QOL is commonly used and consists of 22 items, all of which use a five-point ordinal response scale in which 1 = extremely, 2 = quite a bit, 3 = moderately, 4 = a little, and 5 = not at all.

I-QOL scores are transformed to a 0-100 scale for easy interpretability. Higher scores indicate better quality of life.

Scale score = ((The sum of the items - lowest possible score) / Possible raw score range ) x 100.

Questionnaire I-QoL fulfilled before implantation and 3 months after activation of AUS.

3 months after activation of the AUS is corresponding to 32 weeks from the inclusion (8 months).

Trial Locations

Locations (1)

Service d'Urologie, Hôpital Pitié-Salpêtrière

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath